AZN 241220 80.00P (AZN241220P80000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

AZN241220P80000

Watchlist

13.00
-0.02-0.15%

15min DelayClose Dec 16 16:00 ET

13.00High13.00Low

Intraday

5D
Daily

News

Promise Bio Emerges From Stealth With $8.3M Seed Investment to Transform Precision Medicine for Immune-Mediated Diseases
PR NewswireDec 16 03:00 ET
AstraZeneca Strengthens Board With New Non-Executive Director Appointments
TipRanksDec 16 02:40 ET
AstraZeneca: Appointments Are Effective From Jan. 1, Feb. 1 Respectively
Dow JonesDec 16 02:02 ET
AstraZeneca: Rene Haas and Birgit Conix Appointed as Non-Executive Directors
Dow JonesDec 16 02:02 ET
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
BenzingaDec 13 12:15 ET
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
BenzingaDec 13 11:16 ET

Comments

10xStockPicks

22 hours ago

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Yesterday 05:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...